Shandong Boan Biotechnology (6955) Stock Overview
A biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
6955 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shandong Boan Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.46 |
| 52 Week High | HK$25.00 |
| 52 Week Low | HK$7.51 |
| Beta | -0.33 |
| 1 Month Change | -16.92% |
| 3 Month Change | -36.30% |
| 1 Year Change | 13.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.17% |
Recent News & Updates
Shandong Boan Biotechnology's (HKG:6955) Anemic Earnings Might Be Worse Than You Think
Oct 06
The Market Doesn't Like What It Sees From Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Revenues Yet As Shares Tumble 27%
Sep 08Recent updates
Shandong Boan Biotechnology's (HKG:6955) Anemic Earnings Might Be Worse Than You Think
Oct 06The Market Doesn't Like What It Sees From Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Revenues Yet As Shares Tumble 27%
Sep 08Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) Price Is Right But Growth Is Lacking After Shares Rocket 31%
Jul 24We Think Shandong Boan Biotechnology (HKG:6955) Is Taking Some Risk With Its Debt
May 23Shandong Boan Biotechnology Co., Ltd.'s (HKG:6955) 48% Price Boost Is Out Of Tune With Revenues
Apr 17Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking
Mar 26Shareholder Returns
| 6955 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.4% | 2.2% | -1.3% |
| 1Y | 13.2% | 115.9% | 29.6% |
Return vs Industry: 6955 underperformed the Hong Kong Biotechs industry which returned 115.9% over the past year.
Return vs Market: 6955 underperformed the Hong Kong Market which returned 29.6% over the past year.
Price Volatility
| 6955 volatility | |
|---|---|
| 6955 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6955's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 714 | Hua Jiang | www.boan-bio.com |
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial.
Shandong Boan Biotechnology Co., Ltd. Fundamentals Summary
| 6955 fundamental statistics | |
|---|---|
| Market cap | HK$6.51b |
| Earnings (TTM) | HK$34.97m |
| Revenue (TTM) | HK$826.25m |
Is 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6955 income statement (TTM) | |
|---|---|
| Revenue | CN¥756.78m |
| Cost of Revenue | CN¥214.18m |
| Gross Profit | CN¥542.61m |
| Other Expenses | CN¥510.58m |
| Earnings | CN¥32.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.051 |
| Gross Margin | 71.70% |
| Net Profit Margin | 4.23% |
| Debt/Equity Ratio | 39.4% |
How did 6955 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/01 23:41 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Boan Biotechnology Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chen Chen | UBS Investment Bank |